Biotech company Aimmune has announced plans to file its potential peanut allergy treatment at the end of the year following its major phase 3 trial success. Aimmune saw its shares surge last month ...

Almost exactly three years after agreeing on a $2.6 billion deal to acquire Aimmune Therapeutics and its peanut allergy therapy Palforzia, food group Nestle has sold off the business. This morning ...

European Commission Approves the Extension of the Indication of Palforzia® to the Treatment of Toddlers With Confirmed Peanut Allergy ...